Archive for July, 2008
Pharmaceutical start-ups: Phytomedics
I read today about a really interesting pharmaceutical company that, though it’s considered a start-up, has spent the last 12 years researching and developing new drugs and methodologies that will allow for more rapid and safer development of drug products: Phytomedics. Their focus is on botanical drugs, which, in theory, could provide many of [...]
The Agonist/Antagonist Duel for Enhanced Pharmaceuticals
This is the first posting from Scott Alexander. For more information about Scott, click the Author link on this page.
One of the persistent challenges of the Pharmaceutical industry has been maintaining the safety and efficacy of drug products in patients over time. In other words, when a patient starts taking the drug, the patient [...]
A Perspective on Clinical Statistics: Getting Beyond the Sizzle
Today’s blog comes to us from Georgette Asherman, founder of Direct Effects. She was one of the first writers in the early days of our blog, providing us with the article, “Sample Size Calculations: Thinking About Effect Size.” She has been a professional statistician in pharmaceuticals, consumer products, business services and public policy for [...]
8 Drugs your Doctor Won’t Take?
I was flipping through my June Men’s Health magazine when I came across an article entitled, “8 Drugs Doctors Would Never Take,” written by Morgan Lord. Unfortunately, it’s unclear to me how Lord compiled this list, or weighted the pharmaceuticals that are on it, though I don’t disagree that some of the drugs he [...]
Pharmaceutical Start-ups: WellGen
On April 7th, I had the opportunity to attend the biannual Pharm Fest at Montclair State University. It was a well-organized and interesting event, with several seminars of interest. I wish I could write a full-fledged article on each of the panelists I heard from during that seminar, because I believe they’re all [...]
Loading ...